Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28306830 | 0.87 | KDM4E (0.40) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL30098629 | 0.86 | NCF1 (0.50) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL736202 | 0.86 | NCF1 (0.50) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL566054 | 0.80 | MAPT (0.52) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL2009861 | 0.80 | MAPT (0.52) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL6850673 | 0.77 | MAPT (0.48) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL6850596 | 0.77 | ACACB (0.45) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL28307763 | 0.77 | NCF1 (0.39) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL6894903 | 0.75 | FABP7 (0.39) | CYP3A4ALDH1A1CA1CA2CYP19A1 | |
| SCHEMBL6854179 | 0.74 | ERN1 (0.46) | MAPTKDM4EPOLBCYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019117733-A1 | THE USE OF ACETYLENE DERIVATIVES IN RUMINANTS | PASTORAL GREENHOUSE GAS RESEARCH LTD (NZ) | 2019-06-20 | — | — | WO | disclosed |
| US-20190010158-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | TAIHO PHARMACETUICAL CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| US-10174040-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3395345-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9963456-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2018-05-08 | — | — | US | disclosed |
| EP-3103802-B1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-20170066772-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| EP-3103802-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-12-14 | — | — | EP | disclosed |
| EP-1847545-B1 | SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | UBE INDUSTRIES (JP) | 2013-03-06 | — | — | EP | disclosed |
| CN-101111499-B | Substituted ethynyl gold-nitrogen-containing heterocyclic carbene complex and organic electroluminescent device using the same | UBE INDUSTRIES | 2012-05-23 | — | — | CN | disclosed |
| US-8137821-B2 | Substituted ethynyl gold-nitrogen containing heterocyclic carbene complex and organic electroluminescent device using the same | UBE INDUSTRIES, LTD. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090091243-A1 | Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same | UBE INDUSTRIES, LTD. (JP) | 2009-04-09 | — | — | US | disclosed |
| CN-101111499-A | Substituted ethynyl gold-nitrogenated heterocyclic carbene complex and organic electroluminescent device using same | UBE INDUSTRIES (JP) | 2008-01-23 | — | — | CN | disclosed |
| EP-1847545-A1 | SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | Ube Industries, Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010158-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | MCL1, TP53, DPYD | MAPT 4805/4885KDM4E 3124/4885POLB 512/4885 |
| US-10174040-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | KRAS, DPYD, PSTPIP2 | MAPT 3260/4885KDM4E 697/4885POLB 482/4885 |
| US-20170066772-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | WASHC5, NME1, NHERF1 | MAPT 3496/4885KDM4E 938/4885POLB 974/4885 |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | KRAS, DPYD, PSTPIP2 | MAPT 3260/4885KDM4E 697/4885POLB 482/4885 |
| US-20090091243-A1 | Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same | ACSL3, ATXN2L, ACSL1 | MAPT 4507/4885KDM4E 1868/4885POLB 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.